Plasmapheresis for neurological disorders

Expert Review of Neurotherapeutics

Volumn 9, Issue 9, 2009, Pages 1331-1339

  Schröder, Alexandra ^a   Linker, Ralf A ^a   Gold, Ralf ^a  

^a ST JOSEF HOSPITAL   (Germany)

Author keywords

Immunoadsorption; Immunotherapy; Multiple sclerosis; Plasma exchange

Indexed keywords

ANTICOAGULANT AGENT; AUTOANTIBODY; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT;

ANTICOAGULANT THERAPY; CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; LONG TERM CARE; MULTIPLE SCLEROSIS; NEUROLOGIC DISEASE; PARANEOPLASTIC SYNDROME; PARAPROTEINEMIA; PLASMAPHERESIS; REVIEW; STIFF MAN SYNDROME; VASCULAR ACCESS;

HUMANS; NERVOUS SYSTEM DISEASES; PLASMAPHERESIS; TREATMENT OUTCOME;

EID: 70349439268     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/ern.09.81     Document Type: Review

References (83)

1. Yeh JH, Cheng CK, Chiu HC. A case report of double-filtration plasmapheresis for the treatment of age-related macular degeneration. Ther. Apher. Dial. 12(6), 500-504 (2008).
2. Couriel D, Weinstein R. Complications of therapeutic plasma exchange: a recent assessment. J. Clin. Apher. 9(1), 1-5 (1994). (Pubitemid 24093899)
3. Mokrzycki MH, Kaplan AA. Therapeutic plasma exchange: complications and management. Am. J. Kidney Dis. 23(6), 817-827 (1994).
4. Arbiser JL, Dzieczkowski JS, Harmon JV et al. Leukocytoclastic vasculitis following staphylococcal protein A column immunoadsorption therapy: two cases and a review of the literature. Arch. Dermatol. 131(6), 707-709 (1995).
5. Braun N, Risler T. Immunoadsorption as a tool for the immunomodulation of the humoral and cellular immune system in autoimmune disease. Ther. Apher. 3(3), 240-245 (1999). (Pubitemid 29353127)
6. Hehmke B, Salzsieder E, Matic GB et al. Immunoadsorption of immunoglobulins alters intracytoplasmic type 1 and type 2 T cell cytokine production in patients with refractory autoimmune diseases. Ther. Apher. 4(4), 296-302 (2000). (Pubitemid 30679527)
7. Stegall MD, Gloor J, Winters JL et al. A comparison of plasmapheresis versus high-dose IVIG desensitization in renal allograft recipients with high levels of donor specific alloantibody. Am. J. Transplant. 6(2), 346-351 (2006). (Pubitemid 43382170)
8. Bengsch S Boos KS, Nagel D. Extracorporeal plasma treatment for the removal of endotoxin in patients with sepsis: clinical results of a pilot study. Shock 23(6), 494-500 (2005). (Pubitemid 40677420)
9. Newsom-Davis J, Vincent A, Wilson SG et al. Plasmapheresis for myasthenia gravis. N. Engl. J. Med. 298(8), 456-457 (1978).
10. Dyck PJ, Kurtzke JF. Plasmapheresis in Guillain-Barré syndrome. Neurology 35(8), 1105-1107 (1985).
11. Hauser SL, Dawson DM, Lehrich JR et al. Immunosuppression and plasmapheresis in chronic progressive multiple sclerosis: design of a clinical trial. Arch. Neurol. 40(11), 687-690 (1983).
12. Ruprecht K, Klinker E, Dintelmann T et al. Plasma exchange for severe optic neuritis: treatment of 10 patients. Neurology 63(6), 1081-1083 (2004). (Pubitemid 39287920)
13. Schilling S, Linker RA, Konig FB et al. Plasma exchange therapy for steroidunresponsive multiple sclerosis relapses: clinical experience with 16 patients. Nervenarzt 77(4), 430-438 (2006).
14. Weinshenker BG, O'Brien PC, Petterson TM et al. A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. Ann. Neurol. 46(6), 878-886 (1999).
15. Watanabe S, Nakashima I, Misu T et al. Therapeutic efficacy of plasma exchange in NMO-IgG-positive patients with neuromyelitis optica. Mult. Scler. 13(1), 128-132 (2007). (Pubitemid 46152772)
16. Hench PS, Kendall EC. The effect of a hormone of the adrenal cortex (17-hydroxy-11-dehydrocorticosterone; compound E) and of pituitary adrenocorticotropic hormone on rheumatoid arthritis. Mayo Clin. Proc. 24(8), 181-197 (1949).
17. Schmidt J, Gold R, Schonrock L et al. T-cell apoptosis in situ in experimental autoimmune encephalomyelitis following methylprednisolone pulse therapy. Brain 123, 1431-1441 (2000). (Pubitemid 30420943)
18. Leussink VI, Jung S, Merschdorf U et al. High-dose methylprednisolone therapy in multiple sclerosis induces apoptosis in peripheral blood leukocytes. Arch. Neurol. 58(1), 91-97 (2001). (Pubitemid 32053212)
19. Dowling PC, Bosch VV, Cook SD. Possible beneficial effect of high-dose intravenous steroid therapy in acute demyelinating disease and transverse myelitis. Neurology 30, 33-36 (1980).
20. Bracken MB, Shepard MJ, Collins WF et al. A randomized, controlled trial of methylprednisolone or naloxone in the treatment of acute spinal-cord injury: results of the Second National Acute Spinal Cord Injury study. N. Engl. J. Med. 322(20), 1405-1411 (1990).
21. Milligan NM, Newcombe R, Compston DA. A double-blind controlled trial of high dose methylprednisolone in patients with multiple sclerosis: 1. Clinical effects. J. Neurol. Neurosurg. Psychiatry 50(5), 511-516 (1987). (Pubitemid 17067536)
22. Beck RW, Cleary PA, Anderson MM Jr et al. A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis: the Optic Neuritis study group. N. Engl. J. Med. 326(9), 581-588 (1992).
23. Oliveri RL, Valentino P, Russo C et al. Randomized trial comparing two different high doses of methylprednisolone in MS: a clinical and MRI study. Neurology 50(6), 1833-1836 (1998).
24. Miller DH, Thompson AJ, Morrissey SP et al. High dose steroids in acute relapses of multiple sclerosis: MRI evidence for a possible mechanism of therapeutic effect. J. Neurol. Neurosurg. Psychiatry 55(6), 450-453 (1992).
25. Rieckmann P, Toyka KV, Bassetti C et al. Escalating immunotherapy of multiple sclerosis - new aspects and practical application. J. Neurol. 251(11), 1329-1339 (2004).
26. Lassmann H, Bruck W, Lucchinetti C. Heterogeneity of multiple sclerosis pathogenesis: implications for diagnosis and therapy. Trends Mol. Med. 7(3), 115-121 (2001). (Pubitemid 32201673)
27. Lassmann H, Bruck W, Lucchinetti CF. The immunopathology of multiple sclerosis: an overview. Brain Pathol. 17(2), 210-218 (2007).
28. Gold R, Buttgereit F, Toyka KV. Mechanism of action of glucocorticosteroid hormones: possible implications for therapy of neuroimmunological disorders. J. Neuroimmunol. 117(1-2), 1-8 (2001). (Pubitemid 32595488)
29. Keegan M, Pineda AA, McClelland RL et al. Plasma exchange for severe attacks of CNS demyelination: predictors of response. Neurology 58(1), 143-146 (2002). (Pubitemid 34041955)
30. Keegan M, Konig F, McClelland R et al. Relation between humoral pathological changes in multiple sclerosis and response to therapeutic plasma exchange. Lancet 366(9485), 579-582 (2005). (Pubitemid 41140333)
31. Tselis A, Perumal J, Caon C et al. Treatment of corticosteroid refractory optic neuritis in multiple sclerosis patients with intravenous immunoglobulin. Eur. J. Neurol. 15(11), 1163-1167 (2008).
32. Linker RA, Chan A, Sommer M et al. Plasma exchange therapy for steroidrefractory superimposed relapses in secondary progressive multiple sclerosis. J. Neurol. 254(9), 1288-1289 (2007). (Pubitemid 350112345)
33. Zettl UK, Hartung HP, Pahnke A et al. Lesion pathology predicts response to plasma exchange in secondary progressive MS. Neurology 67(8), 1515-1516 (2006). (Pubitemid 44632095)
34. Lennon VA, Wingerchuk DM, Kryzer TJ et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 364(9451), 2106-2112 (2004).
35. Lennon VA, Kryzer TJ, Pittock SJ et al. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J. Exp. Med. 202(4), 473-477 (2005).
36. Moldenhauer A, Haas J, Wascher C et al. Immunoadsorption patients with multiple sclerosis: an open-label pilot study. Eur. J. Clin. Invest. 35(8), 523-530 (2005). (Pubitemid 41153207)
37. Palm M, Behm E, Schmitt E et al. Immunoadsorption and plasma exchange in multiple sclerosis: complement and plasma protein behaviour. Biomater. Artif. Cells Immobilization Biotechnol. 19(1), 283-296 (1991).
38. Schröder A, Fischer M, Meyer C et al. Plasmapherese in der Eskalationstherapie der Multiplen Sklerose: Verlaufsbeobachtung an 35 Patienten. Akt. Neurol. 36, 105-1100 (2009).
39. Odaka M, Yuki N, Yamada M et al. Bickerstaff 's brainstem encephalitis: clinical features of 62 cases and a subgroup associated with Guillain-Barré syndrome. Brain 126, 2279-2290 (2003). (Pubitemid 37432371)
40. Fujisato H, Amemiya M, Hayashi Y et al. Treatment with steroids and double filtration plasmapheresis for a case of anti-GQ1b antibody-positive Bickerstaff's encephalitis. Ther. Apher. 3(1), 72-74 (1999). (Pubitemid 29133874)
41. Markus R, Brew BJ, Turner J et al. Successful outcome with aggressive treatment of acute haemorrhagic leukoencephalitis. J. Neurol. Neurosurg. Psychiatry 63(4), 551 (1997). (Pubitemid 27423573)
42. Seales D, Greer M. Acute hemorrhagic leukoencephalitis: a successful recovery. Arch. Neurol. 48(10), 1086-1088 (1991).
43. Murai H, Arahata H, Osoegawa M et al. Effect of immunotherapy in myelitis with atopic diathesis. J. Neurol. Sci. 227(1), 39-47 (2004). (Pubitemid 39491124)
44. Mori M, Kuwabara S, Yoshiyama M et al. Successful immune treatment for non-paraneoplastic limbic encephalitis. J. Neurol. Sci. 201(1-2), 85-88 (2002). (Pubitemid 34876910)
45. Miyamoto K, Kato T, Watanabe H et al. A case of paraneoplastic syndrome accompanied by two types of cancer. J. Neurol. Neurosurg. Psychiatry 72(3), 408-409 (2002). (Pubitemid 34185220)
46. Sommer C, Weishaupt A, Brinkhoff J et al. Paraneoplastic stiff-person syndrome: passive transfer to rats by means of IgG antibodies to amphiphysin. Lancet 365(9468), 1406-1411 (2005). (Pubitemid 40523735)
47. Shariatmadar S, Noto TA. Plasma exchange in stiff-man syndrome. Ther. Apher. 5(1), 64-67 (2001).
48. Buckley C, Oger J, Clover L et al. Potassium channel antibodies in two patients with reversible limbic encephalitis. Ann. Neurol. 50(1), 73-78 (2001).
49. Vincent A, Buckley C, Schott JM et al. Potassium channel antibody-associated encephalopathy: a potentially immunotherapy-responsive form of limbic encephalitis. Brain 127, 701-712 (2004). (Pubitemid 38295483)
50. Seki M, Suzuki S, Iizuka T et al. Neurological response to early removal of ovarian teratoma in anti-NMDAR encephalitis. J. Neurol. Neurosurg. Psychiatry 79(3), 324-326 (2008). (Pubitemid 351303394)
51. Mata S, Muscas GC, Naldi I et al. Non-paraneoplastic limbic encephalitis associated with anti-glutamic acid decarboxylase antibodies. J. Neuroimmunol. 199(1-2), 155-159 (2008).
52. Rogers SW, Andrews PI, Gahring LC et al. Autoantibodies to glutamate receptor GluR3 in Rasmussen's encephalitis. Science 265(5172), 648-651 (1994).
53. Basic-Jukic N, Kes P, Bubic-Filipi L et al. Treatment of thrombotic microangiopathies with plasma exchange. Hematology 12(1), 63-67 (2007). (Pubitemid 46394872)
54. Thompson CE, Damon LE, Ries CA et al. Thrombotic microangiopathies in the 1980s: clinical features, response to treatment, and the impact of the human immunodeficiency virus epidemic. Blood 80(8), 1890-1895 (1992).
55. Kato T, Shiratori K, Kobashigawa T et al. Systemic lupus erythematosus with organic brain syndrome: serial electroencephalograms accurately evaluate therapeutic efficacy. Intern. Med. 45(2), 95-99 (2006). (Pubitemid 43285896)
56. Bril V, Ilse WK, Pearce R et al. Pilot trial of immunoglobulin versus plasma exchange in patients with Guillain-Barré syndrome. Neurology 46(1), 100-103 (1996). (Pubitemid 126425727)
57. van der Meche FG, Schmitz PI. A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrome: Dutch Guillain-Barré study group. N. Engl. J. Med. 326(17), 1123-1129 (1992).
58. Anonymous. Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain- Barré syndrome: Plasma Exchange/ Sandoglobulin Guillain-Barré Syndrome trial group. Lancet 349(9047), 225-230 (1997).
59. Korinthenberg R, Schessl J, Kirschner J et al. Intravenously administered immunoglobulin in the treatment of childhood Guillain-Barré syndrome: a randomized trial. Pediatrics 116(1), 8-14 (2005).
60. Arakawa H, Yuhara Y, Todokoro M et al. Immunoadsorption therapy for a child with Guillian-Barre syndrome subsequent to Mycoplasma infection: a case study. Brain Dev. 27(6), 431-433 (2005). (Pubitemid 41188686)
61. Mori M, Kuwabara S, Fukutake T et al. Intravenous immunoglobulin therapy for Miller Fisher syndrome. Neurology 68(14), 1144-1146 (2007). (Pubitemid 46559850)
62. Dyck PJ, Daube J, O'Brien P et al. Plasma exchange in chronic inflammatory demyelinating polyradiculoneuropathy. N. Engl. J. Med. 314(8), 461-465 (1986). (Pubitemid 16161945)
63. Hahn AF, Bolton CF, Pillay N et al. Plasma-exchange therapy in chronic inflammatory demyelinating polyneuropathy: a double-blind, shamcontrolled, cross-over study. Brain 119, 1055-1066 (1996). (Pubitemid 26300708)
64. Mehndiratta MM, Hughes RA, Agarwal P. Plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst. Rev. (3), CD003906 (2004).
65. Haas DC, Tatum AH. Plasmapheresis alleviates neuropathy accompanying IgM anti-myelin-associated glycoprotein paraproteinemia. Ann. Neurol. 23(4), 394-396 (1988).
66. Azulay JP, Blin O, Pouget J et al. Intravenous immunoglobulin treatment in patients with motor neuron syndromes associated with anti-GM1 antibodies: a double-blind, placebo-controlled study. Neurology 44(3 Pt 1), 429-432 (1994). (Pubitemid 24098139)
67. Federico P, Zochodne DW, Hahn AF et al. Multifocal motor neuropathy improved by IVIg: randomized, double-blind, placebocontrolled study. Neurology 55(9), 1256-1262 (2000). (Pubitemid 30829363)
68. Leger JM, Chassande B, Musset L et al. Intravenous immunoglobulin therapy in multifocal motor neuropathy: a doubleblind, placebo-controlled study. Brain 124, 145-153 (2001). (Pubitemid 32055996)
69. van den Berg LH, Kerkhoff H, Oey PL et al. Treatment of multifocal motor neuropathy with high dose intravenous immunoglobulins: a double blind, placebo controlled study. J. Neurol. Neurosurg. Psychiatry 59(3), 248-252 (1995).
70. Gorson KC Natarajan N, Ropper AH et al. Rituximab treatment in patients with IVIg-dependent immune polyneuropathy: a prospective pilot trial. Muscle Nerve 35(1), 66-69 (2007).
71. Gajdos P, Chevret S, Toyka K. Plasma exchange for myasthenia gravis. Cochrane Database Syst. Rev. (4), CD002275 (2002).
72. Gajdos P, Chevret S, Clair B et al. Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis: Myasthenia Gravis Clinical study group. Ann. Neurol. 41(6), 789-796 (1997).
73. Qureshi AI, Choudhry MA, Akbar MS et al. Plasma exchange versus intravenous immunoglobulin treatment in myasthenic crisis. Neurology 52(3), 629-632 (1999).
74. Gold R, Schneider-Gold C. Current and future standards in treatment of myasthenia gravis. Neurotherapeutics 5(4), 535-541 (2008).
75. Newsom-Davis J, Murray NM. Plasma exchange and immunosuppressive drug treatment in the Lambert-Eaton myasthenic syndrome. Neurology 34(4), 480-485 (1984). (Pubitemid 14127311)
76. Alessi G, De RJ, De BJ et al. Successful immunoglobulin treatment in a patient with neuromyotonia. Clin. Neurol. Neurosurg. 102(3), 173-175 (2000).
77. van den Berg JS, van Engelen BG, Boerman RH et al. Acquired neuromyotonia: superiority of plasma exchange over high-dose intravenous human immunoglobulin. J. Neurol. 246(7), 623-625 (1999).
78. Herson S, Lok C, Roujeau JC et al. Plasma exchange in dermatomyositis and polymyositis: retrospective study of 38 cases of plasma exchange. Ann. Med. Interne (Paris) 140(6), 453-455 (1989). (Pubitemid 20005209)
79. Chan A, Weilbach FX, Toyka KV et al. Mitoxantrone induces cell death in peripheral blood leucocytes of multiple sclerosis patients. Clin. Exp. Immunol. 139(1), 152-158 (2005). (Pubitemid 40066141)
80. Bar-Or A, Calabresi PA, Arnold D et al. Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, Phase I trial. Ann. Neurol. 63(3), 395-400 (2008). (Pubitemid 351240747)
81. Hauser SL, Waubant E, Arnold DL et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N. Engl. J. Med. 358(7), 676-688 (2008). (Pubitemid 351240747)
82. Linker RA, Lee DH, Stangel M, Gold R. Fumarates for the treatment of multiple sclerosis: potential mechanisms of action and clinical studies. Expert Rev Neurother. 8(11), 1683-1690 (2008).
83. USA clinical trials www.clinicaltrials.gov